NO. 4 THE FORUM, ST. HELIER, Y9
Reg. FD
Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
Election of Directors at NovoCure Limited Annual Meeting
Reports First Quarter 2026 Financial Results
Amended material disclosure
Chief Medical Officer Assignment
Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
S-8 POS